Stephens Jacqueline M, Vidal-Puig Antonio J
Department of Clinical Biochemistry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Curr Opin Lipidol. 2006 Apr;17(2):128-31. doi: 10.1097/01.mol.0000217893.77746.4b.
The aim of this article is to summarize all of the recent studies on pre-B cell colony-enhancing factor visfatin, a ubiquitously expressed secreted protein that has been implicated in obesity and insulin resistance. Although pre-B-cell colony-enhancing factor was discovered over 10 years ago, there are many remaining questions about the regulation and function of this protein.
Studies in the last decade have revealed the endocrine properties of fat cells. One of the most recent proteins shown to be highly expressed in adipose tissue is visfatin, originally identified as pre-B-cell colony-enhancing factor. Visfatin/pre-B-cell colony-enhancing factor appears to be preferentially produced by the visceral adipose tissue and has insulin mimetic actions. Studies by many groups indicate that obesity-related diabetes and accompanying metabolic disorders in humans have been specifically linked to increased visceral adipose tissue mass. The different roles of various adipocyte depots, however, are still poorly understood. It has been hypothesized that understanding the differences in the biology of visceral and subcutaneous human adipose tissue may hold the key to therapeutic strategies aimed at reducing obesity-induced insulin resistance and alleviating symptoms of the metabolic syndrome. Interestingly, some observed actions of visfatin indicate that this secreted protein may be an interesting therapeutic target. Several recent studies, however, indicate that our understanding of visfatin is still speculative.
This review summarizes all of the papers in the last year on the expression and function of visfatin/pre-B-cell colony-enhancing factor and highlights inconsistent observations from various investigators studying this protein. It also highlights previous observations on the role of pre-B-cell colony-enhancing factor. We suggest that the pathophysiologic role of visfatin/pre-B-cell colony-enhancing factor in humans remains largely unknown.
本文旨在总结近期所有关于前B细胞集落增强因子内脂素的研究，内脂素是一种广泛表达的分泌蛋白，与肥胖和胰岛素抵抗有关。尽管前B细胞集落增强因子在10多年前就已被发现，但关于该蛋白的调节和功能仍存在许多问题。
过去十年的研究揭示了脂肪细胞的内分泌特性。最近发现的一种在脂肪组织中高表达的蛋白是内脂素，最初被鉴定为前B细胞集落增强因子。内脂素/前B细胞集落增强因子似乎主要由内脏脂肪组织产生，并具有胰岛素模拟作用。许多研究小组的研究表明，人类肥胖相关糖尿病及伴随的代谢紊乱与内脏脂肪组织量增加密切相关。然而, 不同脂肪细胞储存库的不同作用仍知之甚少。据推测，了解人类内脏和皮下脂肪组织生物学上的差异可能是旨在降低肥胖诱导的胰岛素抵抗和缓解代谢综合征症状的治疗策略的关键。有趣的是，内脂素的一些观察到的作用表明这种分泌蛋白可能是一个有趣的治疗靶点, 然而，最近的几项研究表明，我们对内脂素的理解仍然是推测性的
本综述总结了去年所有关于内脂素/前B细胞集落增强因子表达和功能的论文，并强调了研究该蛋白的不同研究者之间不一致观察结果。它还强调了以前关于前B细胞集落增强因子作用的观察结果。我们认为，内脂素/前B细胞集落增强因子在人类病理生理中的作用在很大程度上仍然未知
